Searchable abstracts of presentations at key conferences in endocrinology

ea0026p46 | Endocrine disruptors | ECE2011

Bone remodeling parameters and bone mass in patients with schizophrenia treated with long-acting injectable risperidone

Doknic M , Bojovic N Maric , Pekic S , Britvic D , Damjanovic A , Gasic M Jasovic , Popovic V

Introduction: Studies suggest that schizophrenia and prolactin raising antipsychotics, one of them being risperidone, may be associated with low bone mass. On the other hand, weight gain as a consequence of antipsychotics in these patients may be the protective factor against osteoporosis.Objective: Determine bone remodeling parameters and bone mass in patients with schizophrenia treated with long-acting injectable risperidone (LAIR) under naturalistic c...

ea0029p1145 | Neuroendocrinology | ICEECE2012

Relationship between leptin, markers of bone turnover, bone mineral density, and body weight in patients with schizophrenia treated with long acting risperidone (LAIR)

Doknic M. , Maric N. , Britvic D. , Pekic S. , Miljic D. , Stojanovic M. , Damjanovic A. , Jasovic-Gasic M. , Popovic V.

Introduction: Leptin, adipose-tissue-derived hormone has a prominent role in bone remodeling by activating, through CNS relay, the sympathetic tone which inhibits bone formation. Schizophrenia is a CNS disease associated with low bone mass and changes in bone remodeling. Risperidone, atypical antipsychotic, may be related to increase in body weight (BW). Increased BW is thought to be protective to the bone.Aim: To determine relations between leptin, bone...